Baltazar, Neriza N.
HRN: 23-20-40 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2023
CO-AMOXICLAV 625MG (TAB)
11/30/2023
12/06/2023
ORAL
625mg
BID
NSVD With Right Mediolateral Episiorrhapy
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes